Industry News

ImClone Systems Expands Program in Cancer-Related Angiogenesis

Published in Cancer Weekly, November 17th, 1997

ImClone Systems Inc., New York, New York, announced that the company has acquired exclusive rights to a recently discovered protein which may play an important role in the early growth of cancers.

This protein, referred to as VE-cadherin-2, is believed to enable the formation of a capillary blood vessel network in solid tumors, an essential step in the uncontrolled growth of malignancies. ImClone Systems is developing antagonists to VE-cadherin-2 to inhibit tumor vascularization.

In connection with its acquisition of exclusive relevant patent applications, the company initiated a collaboration with Mario Negri Institute (Milan, Italy) to conduct...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry